Immune checkpoint inhibitors in lung cancer: Past, present and future

Future Oncology

Volumn 12, Issue 9, 2016, Pages 1151-1163

  Seetharamu, Nagashree ^a   Budman, Daniel R ^a   Sullivan, Kevin M ^a  

^a North Shore Long Island Center for Advanced Medicine   (United States)

Author keywords

atezolizumab; CTLA 4; durvalumab; immunotherapy; ipilimumab; nivolumab; NSCLC; PD 1; PD L1; pembrolizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ATEZOLIZUMAB; CHECKPOINT KINASE INHIBITOR; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LYMPHOCYTE ANTIGEN RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; DIARRHEA; FATIGUE; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNE RESPONSE; LUNG CANCER; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; LUNG NEOPLASMS;

ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CTLA-4 ANTIGEN; HUMANS; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL;

EID: 84965149585     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.16.20     Document Type: Review

References (79)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65(1), 5-29 (2015).
2. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
3. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3. trial. Lancet Oncol. 13(3), 239-246 (2012).
4. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3327-3334 (2013).
5. Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 371(21), 1963-1971 (2014).
6. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368(25), 2385-2394 (2013).
7. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511), 543-550 (2014).
8. Seetharamu N. The state of the art in non-small cell lung cancer immunotherapy. Semin. Thorac. Cardiovasc. Surg. 26(1), 26-35 (2014).
9. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
10. Winter H, Van Den Engel NK, Rusan M et al. Active-specific immunotherapy for non-small cell lung cancer. J. Thorac. Dis. 3(2), 105-114 (2011).
11. Pardoll D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807-839 (2003).
12. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263-274 (2005).
13. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012).
14. Wang CJ, Heuts F, Ovcinnikovs V et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc. Natl Acad. Sci. USA 112(2), 524-529 (2015).
15. Wei T, Zhang J, Qin Y et al. Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients. Am. J. Cancer Res. 5(7), 2190-2201 (2015).
16. Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
17. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol. 30(17), 2046-2054 (2012).
18. Clinical trials database: NCT02279732. https://clinicaltrials.gov
19. Clinical trials database: NCT02221739. https://clinicaltrials.gov
20. Clinical trials database: NCT02477826. https://clinicaltrials.gov
21. Zhou ZJ, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl. Lung Cancer Res. 4(2), 203-208 (2015).
22. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123-135 (2015).
23. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018-2028 (2015).
24. Clinical trials database: NCT01642004. https://clinicaltrials.gov
25. Paz-Ares L, Borghaei H, Spigel DR, Steins M. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Presented at: ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May-2 June 2015 (Abstract LBA109).
26. Clinical trials database: NCT01673867. https://clinicaltrials.gov
27. Clinical trials database: NCT01295827. https://clinicaltrials.gov
28. Spira AI, Park KG, Mazieres J, Vansteenkiste J, Rittmeyer A. Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). Presented at: ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May-2 June 2015 (Abstract 8010).
29. Clinical trials database: NCT01903993. https://clinicaltrials.gov
30. Spigel DR, Chaft JE, Gettinger SN. Clinical activity and safety from a Phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33(Suppl.), Abstract 8028 (2015).
31. Clinical trials database: NCT01846416. https://clinicaltrials.gov
32. Rizvi NA, Brahmer J, Ignatius S, Segal NH. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Presented at: ASCO Annual Meeting 2015. Chicago, IL, USA,29 May-2 June 2015 (Abstract 8032).
33. Clinical trials database: NCT01693562. https://clinicaltrials.gov
34. Papadimitrakopoulou V, Patnaik A, Borghaei H. Pembrolizumab (pembro MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. Presented at: ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May-2 June 2015.
35. Clinical trials database: NCT02039674. https://clinicaltrials.gov
36. Patnaik A, Socinsky MA, Gubens M. Phase I study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. Presented at: 16th World Conference on Lung Cancer. Denver, CO, USA, 6-9 September 2015.
37. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
38. Gettinger SN, Horn L, Gandhi L et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33(18), 2004-2012 (2015).
39. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
40. Rizvi NA, Mazieres J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a Phase 2, single-arm trial. Lancet Oncol. 16(3), 257-265 (2015).
41. Reckamp KL, Spigel DR, Rizvi NA. Phase 3, Randomized Trial (CheckMate 017) of Nivolumab (NIVO) vs Docetaxel in Advanced Squamous (SQ) Cell Non-Small Cell Lung Cancer (NSCLC). Presented at: 16th World Conference on Lung Cancer. Denver, CO, USA, 6-9 September 2015 (Abstract 736).
42. Clinical trials database: NCT02041533. https://clinicaltrials.gov
43. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372(26), 2521-2532 (2015).
44. Pembrolizumab Shows Promise for NSCLC. Cancer Discov. 5(6), 572 (2015).
45. Flotten F, Garon EB, Arkenau H. Pembrolizumab 2mg/kg Q3W for previously treated, PD-L1-positive advanced NSCLC. Presented at: 16th World Conference on Lung Cancer. Denver, CO, USA, 6-9 September 2015 (Abstract 3204).
46. Clinical trials database: NCT02142738. https://clinicaltrials.gov
47. Clinical trials database; NCT02220894. https://clinicaltrials.gov
48. Spigel DR, Gettinger SN, Horn L. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-LI antibody in patient with locally advanced or metastatic non-small cell lung cancer (NSCLC). ASCO Annual Meeting 2013. Chicago, IL, USA, 31 May-4 June 2013 (Abstract 8008).
49. Clinical trials database: NCT02031458. https://clinicaltrials.gov
50. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med. Oncol. 28(3), 682-688 (2011).
51. Teixido C, Karachaliou N, Gonzalez-Cao M, Morales-Espinosa D, Rosell R. Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol. Med. 12(2), 87-95 (2015).
52. Dolled-Filhart M, Roach C, Toland G, Musser G. Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC). Presented at: ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May-2 June 2015 (Abstract 11065).
53. Gettinger SN, Shepherd F, Antonia S, Brahmer J, Chow L. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May-3 June 2014 (Abstract 8024).
54. Gettinger SN, Hellmann MD, Shepherd F, Scott J, Antonia S, Brahmer J. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May-2 June 2015 (Abstract 8025).
55. Patel SP, Kurzrock R. PD-L1 Expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14(4), 847-856 (2015).
56. Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20(19), 5064-5074 (2014).
57. Clinical trials database: NCT02367781. https://clinicaltrials.gov
58. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J. Clin. Oncol. 33(31), 3541-3543 (2015).
59. Ibrahim RA, Berman M, Depril V, Humphrey RW. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 3-7 June 2011 (Abstract 8583).
60. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30(21), 2691-2697 (2012).
61. Jaber SH, Cowen EW, Haworth LR et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch. Dermatol. 142(2), 166-172 (2006).
62. Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment. Pharmacol. Ther. 42(4), 406-417 (2015).
63. Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat. Rev. Clin. Oncol. 11(2), 91-99 (2014).
64. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 98(4), 1361-1375 (2013).
65. Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-related pneumonitis during cancer immunotherapy. N. Engl. J. Med. 373(3), 288-290 (2015).
66. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33(18), 2092-2099 (2015).
67. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother. Radiopharm. 24(3), 321-325 (2009).
68. Camidge DR, Liu SV, Powderly JD. Atezolizumab (MPDL3280A) combined with platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a Phase Ib safety and efficacy update. Presented at: 16th World Conference on Lung Cancer. Denver, CO, USA, 6-9 September 2015 (Abstract 2208).
69. Rizvi NA, Antonia S, Chow L. A Phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naïve non-small cell lung cancer (NSCLC) patients (pts). Presented at: ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May-2 June 2015.
70. Rizvi NA, Gettinger SN, Goldman JW. Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 (PD-1)) and ipilimumab in non-small cell lung cancer (NSCLC). Presented at: 16th World Conference on Lung Cancer. Denver, CO, USA, 6-9 September 2015.
71. Garon EB, Sequist LV, Shaw AT. Prior TKI therapy in NSCLC EGFR mutant patients associates with lack of response to anti-PD-1 treatment. Presented at: 16th World Conference on Lung Cancer. Denver, CO, USA, 6-9 September 2015.
72. Gainor J, Sequist LV, Shaw AT. Clinical Correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC). Presented at: ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May-2 June 2015.
73. Clinical trials database: NCT02366143. https://clinicaltrials.gov
74. Clinical trials database: NCT02542293. https://clinicaltrials.gov
75. Clinical trials database: NCT02409342. https://clinicaltrials.gov
76. Clinical trials database: NCT02409355. https://clinicaltrials.gov
77. Clinical trials database: NCT02613507. https://clinicaltrials.gov
78. Clinical trials database: NCT02578680. https://clinicaltrials.gov
79. Clinical trials database: NCT02367794. https://clinicaltrials.gov